TY  - JOUR 
AU  - Campos Pérez, Francisco
AU  - Qin, T.
AU  - Castillo Sánchez, José
AU  - Seo, J. H.
AU  - Arai, K.
AU  - Lo, E. H.
AU  - Waeber, C.
PY  - 2013
SN  - 0039-2499
UR  - http://hdl.handle.net/20.500.11940/2445
AB  - BACKGROUND AND PURPOSE: The sphingosine 1-phosphate receptor agonist fingolimod reduces infarct size in rodent models of stroke and enhances blood-brain barrier integrity. Based on these observations, we hypothesized that combination of fingolimod...
LA  - eng
KW  - Animals
KW  - Cerebral Hemorrhage
KW  - Disease Models, Animal
KW  - Fingolimod Hydrochloride
KW  - Male
KW  - Mice
KW  - Mice, Inbred C57BL
KW  - Neuroprotective Agents
KW  - Propylene Glycols
KW  - Sphingosine
KW  - Thromboembolism
KW  - Time Factors
KW  - Tissue Plasminogen Activator
KW  - Treatment Outcome
TI  - Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model
DO  - 10.1161/STROKEAHA.112.679043
T2  - Stroke
M2  - 505
VL  - 44
ER  -